is fda stopping semaglutide shortage ends as sets deadline for compounders US judge upholds FDA's removal

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 4 in 10 American adults and is closely linked to obesity, type 2 diabetes, and high blood pressure

A new worry in the retatrutide trials is dysesthesia

This may theoretically produce additive effects on weight loss and metabolic parameters, though this interaction has not been extensively studied in controlled trials

People usually get the safest and most effective care by working closely with their primary care provider or a board-certified obesity medicine physician [if they can no longer afford the medication]

Insulin syringes are single-use devices